… Both of these factors affect treatment response and … resection in patients with malignant
gliomas treated with surgery. … Also, functional diffusion mapping based on ADC values …

… functional diffusion mapping (fDM) as a validated imaging biomarker for early and direct
prediction of therapeutic response and survival in patients with primary malignant brain tumors. …

… treatment response. Since contrast enhancement reflects vascular permeability, … time maps
during bevacizumab treatment from the map of best response (first scan after treatment started…

… Patients with previous history of glioma … treatment response (glycolysis and hypoxia), and
have shown direct relevance to the clinical outcomes of a pilot glioblastoma multiforme patient …

… a) and MRI CBV map (b) from a patient with a recurrent glial cell … any treatment, as well as
during and after definitive treatment. … patient evaluation and assessment of treatment response. …

… treatment outcomes, monitor early treatment response, and detect recurrence.20 In a subset
of GBM patients, … in characterizing glioma grades,65 mapping glycine distribution in gliomas,…

… mapping. Furthermore, it can be used as an outcome measure for tracking progression and
response to treatment… consisted largely of lower grade gliomas and the peritumoral region …

… volume map (E) and increased vascular permeability (volume transfer coefficient [Ktrans]
map) (F). (Images courtesy of Robert Young, MD, Memorial Sloan-Kettering Cancer Center.) …

… Various functional/physiologic imaging biomarkers have been used in the past to grade
gliomas, predict survival, and assess treatment response, as well as correlate with …

… Thus, TTFields delivered according to NovoTAL mapping have both high targeting selectivity
… Since TTFields only exert a therapeutic effect when the device is actively utilized and, thus, …